F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma

Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more

Related Keywords

Portugal ,Japan ,Lugano ,Ticino ,Switzerland ,United States ,France ,Belgium ,America ,Nathalie Meetz ,Polatuzumab Vedotin ,Karl Mahler ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Birgit Masjost ,Sileia Urech ,Loren Kalm ,Karsten Kleine ,Genentech ,Lymphoma Study Association ,World Health Organization ,Roche Group ,Roche Group Media Relations ,Lymphoma Academic Research Organisation ,Lugano Response Criteria ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Cancer Incidence ,Previously Untreated Diffuse Largeb Cell ,Hoffmann ,Oche ,Thmp ,Ecommends ,Approval ,Polivy ,Combination ,People ,Reviously ,Untreated ,Diffuse ,Barge ,Fell ,Lymphoma ,